Cargando…

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model

Introduction: Dapagliflozin-induced improvement of glycemic control in patients with inadequately controlled type 1 diabetes (T1D) is complicated by the delicate balance between blood glucose and exogenous insulin. In this work, we developed a semi-mechanistic population exposure-response model usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sokolov, Victor, Yakovleva, Tatiana, Penland, Robert C., Boulton, David W., Tang, Weifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634426/ https://www.ncbi.nlm.nih.gov/pubmed/37954838 http://dx.doi.org/10.3389/fphar.2023.1229255

Ejemplares similares

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
por: Sokolov, Victor, et al.
Publicado: (2018)

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
por: Sokolov, Victor, et al.
Publicado: (2023)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
por: Demin, Oleg, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes
por: SAYED, Noha, et al.
Publicado: (2020)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
por: SAYED, Noha, et al.
Publicado: (2021)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Effect of Astragali radix extract on pharmacokinetic behavior of dapagliflozin in healthy and type 2 diabetic rats
por: Du, Wandi, et al.
Publicado: (2023)

Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase
por: Li, Ping, et al.
Publicado: (2020)

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus
por: Naagaard, M. Daniel, et al.
Publicado: (2022)

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
por: Jo, Heeseung, et al.
Publicado: (2021)

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients
por: Wang, Dong-Dong, et al.
Publicado: (2023)

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial
por: Jiang, Lan-lan, et al.
Publicado: (2021)

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
por: Aberle, Jens, et al.
Publicado: (2020)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Dapagliflozin promotes angiogenesis in hindlimb ischemia mice by inducing M2 macrophage polarization
por: Yang, Heng, et al.
Publicado: (2023)

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
por: Qiao, Panshuang, et al.
Publicado: (2022)

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021)

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease
por: Zou, Meina, et al.
Publicado: (2021)

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice
por: Chang, Dong-Yuan, et al.
Publicado: (2021)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
por: Xing, Yu-jie, et al.
Publicado: (2021)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
por: Yu, Jing, et al.
Publicado: (2021)

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
por: Li, Liuran, et al.
Publicado: (2021)

Rhein for treating diabetes mellitus: A pharmacological and mechanistic overview
por: Deng, Tingting, et al.
Publicado: (2023)

Dose Optimization of Aditoprim-Sulfamethoxazole Combinations Against Trueperella pyogenes From Patients With Clinical Endometritis by Using Semi-mechanistic PK/PD Model
por: Maan, Muhammad Kashif, et al.
Publicado: (2021)

Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2023)

Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin
por: Yesilyurt, Zeynep Elif, et al.
Publicado: (2019)

Commentary: Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
por: Liu, Zengying, et al.
Publicado: (2022)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition
por: Chen, Weixiang, et al.
Publicado: (2023)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kbgercmpqg9ke3agq9madt138f